Products for Research Use Only
RegisterLogin

Itacnosertib

CAT: 0804-HY-109179-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109179-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM) . Itacnosertib exhibits anti-leukemic activity[1][2].
CAS Number
1628870-27-8
Product Name Alternative
TP-0184
UNSPSC
12352005
Target
Akt; Anaplastic lymphoma kinase (ALK) ; FLT3; JAK; mTOR; PI3K; STAT; TGF-beta/Smad; TGF-β Receptor
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/itacnosertib.html
Purity
99.06
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CN1CCN(C2=CC=C(NC3=NC=CC(NC4=CC=CN=C4C5=NC=CC=C5)=N3)C=C2OC)CC1
Molecular Formula
C26H28N8O
Molecular Weight
468.55
References & Citations
[1]Mollard, Alexis; Warner, Steven L.; Flynn, Gary A.; Vankayalapati, Hariprasad; Bearss, David J. Preparation of [ (piperazinylphenyl) amino]pyrimidine derivatives as JAK2 and ALK2 inhibitors. WO2014151871 A2|[2]Tyagi A, et al., TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. 2024 Jan;38 (1) :82-95.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
ALK2; JAK2

Alternative Products

CatalogName
BA4911-1Itacnosertib
T84696-01Itacnosertib (hydrocholide)
E1732-25mgItacnosertib (TP-0184)

Popular Products